Describes cutting edge approaches in the development of anticancer agents for chemotherapy. These new and interdisciplinary approaches are aimed at the development of tumor specific anticancer agents while increasing the potency against drug-resistant tumors. The volume includes an overview of new paradigms for cancer drug discovery and development by NCI, new generation cytotoxic agents, mechanism based enzyme inhibitors as anticancer agents, anti-angiogenesis
agents, antitumor vaccins, and tumor activated prodrugs using immunoconjugates of monoclonal antibodies with cytotoxic agents.